3 results
Approved WMOCompleted
To assess the effect of treatment with 100 mg of FAB122 (edaravone) on disease progression in patients with ALS.
Approved WMORecruiting
The aim of this study is to investigate the efficacy of subcutaneous IFX in the treatment of moderate to severe Crohn*s disease with and without concomitant immunosuppression, as measured by the proportion of patients in corticosteroid-free clinical…
Not approvedWill not start
To assess the effect of treatment with 100 mg of FAB122 (edaravone) on disease progression in patients with ALS.